T. Rowe Price Investment Management, Inc. Cytokinetics Inc Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Cytokinetics Inc stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 9,955,251 shares of CYTK stock, worth $301 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
9,955,251
Previous 10,752,123
7.41%
Holding current value
$301 Million
Previous $506 Million
20.89%
% of portfolio
0.26%
Previous 0.31%
Shares
10 transactions
Others Institutions Holding CYTK
# of Institutions
408Shares Held
127MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$444 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$359 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$242 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$184 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.07MShares$93.1 Million4.32% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $2.85B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...